FDA Okays First-Ever New Drug for Rare Bone Disorder
The retinoid palovarotene reduces abnormal bone growth in children and adults with fibrodysplasia ossificans progressive.
FDA Approvals
source https://www.medscape.com/viewarticle/995579?src=rss
FDA Approvals
source https://www.medscape.com/viewarticle/995579?src=rss
Comments
Post a Comment